Key Players
Competitive Landscape
FMI research indicates that competition remains narrow for physiological neural-response control and wider across waveforms, implant formats and follow-up services. Medtronic and Saluda provides ECAP-controlled closed-loop systems, while Abbott, Boston Scientific, Globus, Nalu and BIOTRONIK offers other neuromodulation choices. Hospitals compares generator type, compatible leads, clinical evidence, MRI conditions and post-implant support. Expansion of automated programming and connected follow-up is anticipated to drive product development in closed-loop spinal cord stimulation market.
Some of the prominent players are focusing on certifications, acquisitions and portfolio expansion in order to increase its presence in chronic pain treatment. Saluda Medical expanded EVA certification during 2026, Boston Scientific completed the Nalu acquisition, and Globus Medical completed acquisition of Nevro during 2025. Abbott launched Eterna in Japan in January 2025. These developments are increasing spinal implants and neuromodulation choices available to hospitals. However, open-loop SCS and peripheral nerve stimulation should not be included in physiological closed-loop revenue without direct feedback-control evidence.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| January 2026: Saluda received European certification for EVA with recognition in Australia. | Centres require faster programming. | Automated neural-response programming is entering more territories. | Local teams can reduce manual setup after product qualification. |
| March 2026: Boston Scientific described completion of the Nalu acquisition. | Pain practices require options matched to pain source. | Large portfolios are adding smaller neuromodulation systems. | Account coverage may expand across chronic-pain applications. |
| April 2025: Globus completed acquisition of Nevro and the HFX platform. | Spine groups are adding chronic-pain technologies. | SCS ownership is moving into wider procedural portfolios. | Existing spine relationships may support product access. |
| January 2025: Abbott launched Eterna in Japan. | Patients and clinicians seek lower charging burden. | Rechargeable SCS systems are becoming smaller. | Hospitals can offer another implant format. |
Representative Company Overview
| Company | Positioning | Verified market-relevant evidence |
|---|---|---|
| Medtronic plc | Physiological closed-loop SCS platform | January 2025 Inceptiv data reported 82% low-back pain responders and 88% closed-loop preference. |
| Saluda Medical Pty Ltd | Physiological closed-loop SCS platform | January 2026 European EVA certification expanded automated ECAP programming. |
| Abbott Laboratories | Broader rechargeable and recharge-free SCS supplier | January 2025 Eterna launch in Japan introduced a smaller rechargeable generator. |
| Boston Scientific Corporation | Broader SCS and chronic-pain portfolio | September 2026 company update described multiple stimulation approaches. |
| Globus Medical, Inc. | Owner of the Nevro HFX SCS business | April 2025 acquisition added the HFX platform. |
| Nalu Medical, Inc. | Miniaturised externally powered neuromodulation architecture | March 2026 update described a battery-free micro-IPG. |
| Biotronik SE & Co. KG | Connected SCS follow-up and remote support | July 2026 Embrace One launch used more than 200 daily data points. |
Research Methodology
As noted by FMI, the competitive assessment includes companies having public evidence of an SCS system, physiological feedback platform, adjacent neuromodulation architecture or post-implant service. Regulator records, official company announcements, product information, clinical publications and corporate filings are used for the assessment. Companies are compared on feedback control, clinical evidence, follow-up support and documented reach. Open-loop SCS and peripheral nerve stimulation are excluded from closed-loop revenue unless the named system meets the feedback-control definition.
